230 related articles for article (PubMed ID: 33313992)
21. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
22. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
[TBL] [Abstract][Full Text] [Related]
24. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
[TBL] [Abstract][Full Text] [Related]
25. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
26. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
[TBL] [Abstract][Full Text] [Related]
28. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
31. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
32. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
33. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Ferri A; Stagni V; Barilà D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
[TBL] [Abstract][Full Text] [Related]
34. Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.
Barrette AM; Bouhaddou M; Birtwistle MR
ACS Chem Neurosci; 2018 Jan; 9(1):118-129. PubMed ID: 28950062
[TBL] [Abstract][Full Text] [Related]
35. A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screening.
Kadioglu O; Bahramimehr F; Dawood M; Mahmoud N; Elbadawi M; Lu X; Bülbül Y; Schulz JA; Krämer L; Urschel MK; Künzli Z; Abdulrahman L; Aboumaachar F; Kadalo L; Nguyen LV; Shaidaei S; Thaher N; Walter K; Besler KC; Spuller A; Munder M; Greten HJ; Efferth T
Comput Biol Med; 2023 May; 157():106781. PubMed ID: 36931205
[TBL] [Abstract][Full Text] [Related]
36. Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates.
Fisher JL; Wilk EJ; Oza VH; Gary SE; Howton TC; Flanary VL; Clark AD; Hjelmeland AB; Lasseigne BN
FEBS Open Bio; 2024 May; 14(5):803-830. PubMed ID: 38531616
[TBL] [Abstract][Full Text] [Related]
37. Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
Pötschke R; Gielen G; Pietsch T; Kramm C; Klusmann JH; Hüttelmaier S; Kühnöl CD
Pediatr Res; 2020 Mar; 87(4):669-676. PubMed ID: 31756732
[TBL] [Abstract][Full Text] [Related]
38. Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
Zhang F; Liu R; Zhang H; Liu C; Liu C; Lu Y
BMC Cancer; 2020 Jul; 20(1):673. PubMed ID: 32682409
[TBL] [Abstract][Full Text] [Related]
39. Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies.
Turkez H; Arslan ME; Tatar A; Mardinoglu A
Neurochem Int; 2021 Oct; 149():105137. PubMed ID: 34293392
[TBL] [Abstract][Full Text] [Related]
40. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
